drugset / Trial / NCT01967784

Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan

NCT01967784

Phase 3 Completed 100 enrolled Sanofi Pasteur, a Sanofi Company
NaSingle-groupOpen-labelPrevention

Summary

The aim of the study is to describe the immunogenicity and safety of the new formulation of Quadrivalent Influenza Vaccine (QIV) for the 2013-2014 season in the Northern Hemisphere (NH) in subjects aged 9 to 17 years in Taiwan Primary Objective: * To describe the immunogenicity of the QIV (split-virion, inactivated) NH seasonal formulation Secondary Objective: * To describe the safety of the QIV (split-virion, inactivated) NH seasonal formulation

Timeline

Start
2013-10
Primary completion
2014-04
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent influenza vaccine Vaccine 0.5 ml Intramuscular

Indications